

Table S2: GPP and plaque psoriasis characteristics stratified by disease severity as defined by PASI

Characteristic	GPP PASI ≤5	GPP PASI ≤5 sample size	Plaque psoriasis PASI ≤5	Plaque psoriasis PASI ≤5 sample size	GPP PASI >5	GPP PASI >5 sample size	Plaque psoriasis PASI >5	Plaque psoriasis PASI >5 sample size
Demographics								
Age, years, mean (SD)	51.3 (15.0)	38	50.5 (14.2)	3096	50.2 (13.5)	22	50.9 (14.5)	1790
Sex, female, n (%)	24 (63.2)	38	1454 (47.0)	3096	12 (54.5)	22	715 (39.9)	1790
Education, n (%)		37		3088		22		1786
High school graduate/GED	14 (37.8)		737 (23.9)		9 (40.9)		451 (25.3)	
College graduate/higher	13 (35.1)		1198 (38.8)		8 (36.4)		641 (35.9)	
Work status, n (%)		38		3091		22		1787
Full time	18 (47.4)		1882 (60.9)		13 (59.1)		1040 (58.2)	
Part Time	-		258 (8.3)		-		140 (7.8)	
Retired	6 (15.8)		499 (16.1)		-		282 (15.8)	
Disabled	8 (21.1)		207 (6.7)		-		161 (9.0)	
Other	-		245 (7.9)		-		164 (9.2)	
Current smoker, n (%)	9 (24.3)	37	492 (16.1)	3063	-	22	327 (18.4)	1773
BMI categorical, n (%)		37		3051		22		1767
≤24.9	6 (16.2)		611 (20.0)		-		316 (17.9)	
25–29.9	8 (21.6)		979 (32.1)		-		508 (28.7)	
≥30	23 (62.2)		1461 (47.9)		12 (54.5)		943 (53.4)	
Disease characteristics								
Psoriasis duration, years		38		3065		22		1775
Mean (SD)	10.8 (10.0)		14.7 (13.5)		14.2 (15.3)		14.6 (13.4)	
Median (IQR)	8.0 (2.0–19.0)		11.0 (3.0–22.0)		11.0 (2.0–24.0)		11.0 (4.0–21.0)	
Psoriatic arthritis, n (%)	21 (55.3)	38	1095 (36.5)	3000	6 (27.3)	22	578 (33.0)	1754
PEST, n (%)		38		3096		22		1790

3+	17 (44.7)		854 (27.6)		6 (27.3)		480 (26.8)	
BSA continuous, %		38		3090		22		1788
Mean (SD)	6.1 (10.4)		4.2 (7.2)		24.3 (16.3)		19.6 (16.9)	
Median (IQR)	2.0 (1.0, 6.0)		2.0 (1.0, 5.0)		20.0 (11.0, 30.0)		14.0 (10.0, 25.0)	
IGA category, n (%)		38		3092		22		1787
0: Clear	-		696 (22.5)		-		-	
1: Almost clear	9 (23.7)		797 (25.8)		-		16 (<1.0)	
2: Mild	13 (34.2)		937 (30.3)		5 (22.7)		192 (10.7)	
3: Moderate	9 (23.7)		598 (19.3)		13 (59.1)		1178 (65.9)	
4: Severe	-		64 (2.1)		-		398 (22.3)	
History of comorbidities, n (%)								
Infections		38		3095		22		1790
All	17 (44.7)		858 (27.7)		12 (54.5)		480 (26.8)	
Serious	5 (13.2)		127 (4.1)		-		67 (3.7)	
Selected pathogens	7 (18.4)		158 (5.1)		-		104 (5.8)	
Hypertension	18 (47.4)	38	1069 (34.6)	3091	10 (45.5)	22	728 (40.7)	1790
Other CVD (e.g. stroke)	-	38	177 (5.7)	3096	-	22	121 (6.8)	1790
Hyperlipidemia	11 (28.9)	38	736 (23.8)	3091	5 (22.7)	22	492 (27.5)	1790
Diabetes mellitus	8 (21.1)	38	385 (12.5)	3091	5 (22.7)	22	323 (18.0)	1790
Asthma	5 (13.2)	38	183 (5.9)	3091	-	22	101 (5.6)	1790
Depression	14 (36.8)	38	528 (17.1)	3091	5 (22.7)	22	306 (17.1)	1790
Anxiety	13 (34.2)	38	542 (17.5)	3091	-	22	295 (16.5)	1790
Treatment, n (%)								
Biologic exposure		38		3096		22		1790
Bio naïve	13 (34.2)		1706 (55.1)		-		952 (53.2)	
1 previous	13 (34.2)		742 (24.0)		-		422 (23.6)	
≥2 previous	12 (31.6)		648 (20.9)		-		416 (23.2)	
Systemic exposure		38		3096		22		1790
Systemic naïve	16 (42.1)		1894 (61.2)		-		1063 (59.4)	
1 previous	15 (39.5)		1001 (32.3)		-		600 (33.5)	
≥2 previous	7 (18.4)		201 (6.5)		-		127 (7.1)	
Phototherapy	16 (42.1)	38	1222 (39.5)	3095	10 (45.5)	22	734 (41.0)	1790

0: None	9 (23.7)		1035 (33.5)		-		167 (9.4)	
1: Small	15 (39.5)		967 (31.3)		8 (36.4)		511 (28.6)	
2: Moderate	-		548 (17.7)		-		463 (25.9)	
3: Very large	9 (23.7)		447 (14.5)		9 (40.9)		565 (31.6)	
4: Extremely large	-		91 (2.9)		-		80 (4.5)	
Patient health state today		38		3084		22		1785
EQ-5D VAS (range 0–100)								
Mean (SD)	65.3 (24.6)		76.6 (19.4)		60.0 (22.5)		69.4 (22.3)	
Median (IQR)	70.0 (50.0–90.0)		80.0 (70.0–90.0)		70.0 (40.0–80.0)		75.0 (60.0–85.0)	
EQ-5D-3L categorical, n (%)		38		3061		22		1765
Walking	13 (34.2)		644 (21.0)		8 (36.4)		460 (26.1)	
Self-care	8 (21.1)		157 (5.1)		5 (22.7)		132 (7.5)	
Usual activities	19 (50.0)		729 (23.8)		7 (31.8)		521 (29.5)	
Pain/discomfort	26 (68.4)		1305 (42.6)		16 (72.7)		989 (56.0)	
Anxiety/depression	18 (47.4)		735 (24.0)		5 (22.7)		507 (28.7)	

BMI, body mass index; BSA, body surface area; CVD, cardiovascular disease; DLQI, Dermatology Life Quality Index; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels; GED, General Education Development; GPP, generalized pustular psoriasis; IGA, Investigator Global Assessment; IQR, interquartile range; PASI, Psoriasis Area Severity Index; PEST, Psoriasis Epidemiology Screening Tool; PGA, Patient Global Assessment; SD, standard deviation; TNFi, tumor necrosis factor inhibitor; VAS, visual analog scale. Only comorbidities with >5% incidence are shown. Categories are not an exhaustive list due to the small sample size.